Propranolol: Comprehensive Clinical Guide

Indications

Propranolol is indicated for cardiovascular conditions (hypertension, angina, arrhythmias, hypertrophic cardiomyopathy), situational/performance anxiety, migraine prophylaxis, essential tremor, hyperthyroidism, and infantile hemangiomas. 1, 2, 3

Cardiovascular Uses

Hypertension: Propranolol is guideline-listed for blood pressure control, though it is not recommended as first-line therapy; ACE inhibitors, ARBs, calcium-channel blockers, and thiazide diuretics are preferred initial agents. 2
Arrhythmias: Rate control in atrial fibrillation and supraventricular tachycardia through slowing sinus rate and increasing AV nodal refractoriness. 3
Hypertrophic cardiomyopathy: For symptomatic patients with exertional gradients, doses up to 480 mg/day may be required. 3
Post-myocardial infarction: Reduces mortality when initiated after acute MI. 4

Psychiatric/Neurological Uses

Situational anxiety: Most effective for performance-related anxiety with prominent somatic symptoms (tremor, palpitations, tachycardia, sweating) rather than chronic generalized anxiety. 2, 3
Inappropriate sinus tachycardia: Particularly in young women (90% female, mean age 38) presenting with palpitations, chest pain, dyspnea, and dizziness triggered by emotional stress. 5
Essential tremor and migraine prophylaxis: Established off-label indications. 4

Dermatologic Use

Infantile hemangiomas: First-line systemic therapy when treatment is required. 1, 3

Adult Dosing Regimens

Situational/Performance Anxiety

Single-dose strategy: 10–20 mg immediate-release taken 30–60 minutes before the anxiety-provoking event; maximum single dose 40 mg. 2, 3
Chronic daily dosing (for frequent episodes): Start 40 mg twice daily (80 mg/day total), titrate to 80–160 mg/day in divided doses; alternatively, long-acting 80 mg once daily, titrated to 120–160 mg once daily. 2, 3

Hypertension

Immediate-release: 80–160 mg/day divided into 2 doses (twice daily). 2, 3
Long-acting: 80 mg once daily, titrated to 120–160 mg once daily. 2

Arrhythmias

Oral immediate-release: 10–40 mg every 6 hours (3–4 times daily). 3
Oral extended-release: 60–160 mg every 12 hours. 3
IV (acute settings): 1 mg over 1 minute, may repeat every 2 minutes up to 3 doses (maximum 3 mg total). 2

Supraventricular Tachycardia

Initial: 30–60 mg/day (divided or single long-acting dose). 2
Maintenance: 40–160 mg/day. 2

Hypertrophic Cardiomyopathy

Up to 480 mg/day for symptomatic patients with exertional gradients. 3

Hyperthyroidism

Doses should be spaced no more than 8 hours apart to maintain adequate beta-blockade. 2
IV for emergency surgical preparation: 0.15 mg/kg achieves rapid blockade within <1 hour. 2

Pediatric Dosing (Infantile Hemangiomas)

Propranolol is the treatment of choice for infantile hemangiomas requiring systemic therapy. 1, 3

Standard Dosing

Initiation: 1 mg/kg/day divided into 2–3 doses with food; increase after 24 hours to maintenance dose of 2 mg/kg/day. 2
Maximum: 3 mg/kg/day for inadequate response. 2
Duration: Most patients do not require treatment beyond 17 months of age. 2

High-Risk Populations (Lower Starting Dose: 0.5 mg/kg/day)

Suspected PHACES syndrome 2
Pre-term infants <48 weeks post-conception 2
Infants <8 weeks old 2
Low birth weight or faltering growth 2
Hyperinsulinism or prior hypoglycemia 2
Poor feeding or metabolic/neurologic disorders 2

Administration Guidelines

Give with or after feeding to reduce hypoglycemia risk. 2
Dosing intervals: ≤8 hours (≤6 hours in younger infants). 2
Hold doses during reduced oral intake, vomiting, or acute illness. 2
Use 5 mg/5 mL oral suspension to minimize dosing errors. 2

Discontinuation

Abrupt cessation is safe for infantile hemangiomas (no taper required). 2

Absolute Contraindications

Screen for these conditions before every propranolol prescription:

Second- or third-degree AV block (without pacemaker) 2, 3, 5
Decompensated heart failure or severe left-ventricular dysfunction 2, 3, 5
Asthma or obstructive airway disease (risk of life-threatening bronchospasm from β₂-blockade) 2, 3, 5
Cardiogenic shock 2, 3, 5
Sinus node dysfunction or sinus bradycardia (without pacemaker) 2, 3, 5
Severe hypotension (systolic BP <90 mm Hg) 2, 5
Recent or ongoing hypoglycemic episodes 2, 3
Known hypersensitivity to propranolol 2, 5

Pre-Treatment Assessment

Mandatory Screening (All Patients)

Cardiovascular examination with auscultation to detect murmurs, gallops, or irregular rhythms. 2
Baseline heart rate and blood pressure measurement. 2
Screen for history of bronchospasm, diabetes, and concurrent medications affecting cardiac conduction (digoxin, amiodarone, calcium-channel blockers). 2

Selective Testing

ECG: Only if abnormal heart rate for age, family history of sudden cardiac death/arrhythmia, syncope, maternal connective-tissue disease, or suspected cardiac abnormality. 2
Echocardiogram: Required for segmental head/neck hemangiomas (PHACES), abnormal cardiac exam, or known cardiac disease. 2
Baseline glucose: In patients at risk for hypoglycemia (pre-term, low weight, faltering growth, neonates, prior hypoglycemia). 2
Routine labs (CBC, renal, liver, thyroid): Not required in otherwise healthy adults or children. 2

PHACES Syndrome (Pediatric)

Brain MRI/MRA before full-dose propranolol. 2
ECG and echocardiogram interpreted by pediatric cardiologist. 2
Discuss arterial stenosis/agenesis with pediatric neurologist. 2

Adverse Effects

Common

Fatigue 2
Bradycardia 2, 3
Hypotension 2, 3
Dizziness 2
Cold extremities (from β₂-mediated vasoconstriction) 2

Serious

Worsening heart failure 2
Bronchospasm (especially in asthma/COPD) 2
Severe bradycardia 2
Masking of hypoglycemia symptoms in diabetic patients (tremor, tachycardia, sweating are blunted; rely on hunger, confusion, or direct glucose monitoring) 2, 3

Rebound Phenomena (Abrupt Discontinuation)

Rebound hypertension 2, 3
Tachycardia 2, 3
Angina 2, 3

Monitoring Parameters

Post-Initiation (High-Risk Pediatric Patients)

Measure heart rate and blood pressure immediately before first dose. 2
Monitor every 30 minutes for 2–4 hours after first dose and after any dose increase ≥0.5 mg/kg. 2

Stable Maintenance Therapy

No routine vital sign monitoring required in stable, asymptomatic adults. 2
Pediatric follow-up every 2–3 months for dose adjustments based on weight. 2

Signs of Excessive Beta-Blockade (Prompt Evaluation Required)

Dizziness or light-headedness 2
Marked fatigue 2
Heart rate <50 bpm 2
Systolic BP <90 mm Hg 2
New or worsening dyspnea/wheezing 2

Acute Illness Management

Temporarily reduce or hold dose during vomiting, diarrhea, or reduced oral intake. 2
Resume at lower dose once oral intake normalizes, then up-titrate. 2

Tapering Recommendations

Cardiovascular Indications (Adults)

Never abruptly discontinue propranolol after chronic use. 2, 3

Taper gradually over 1–3 weeks to prevent rebound hypertension, tachycardia, or angina. 2, 3

Infantile Hemangiomas (Pediatric)

Abrupt cessation is safe (no taper required). 2

Temporary Holds (Acute Illness)

May hold without taper during acute illness with reduced intake or wheezing requiring treatment. 2
Re-start at lower dose and up-titrate once recovered. 2

Drug Interactions

Avoid Routine Combination

Non-dihydropyridine calcium-channel blockers (diltiazem, verapamil): Markedly increased risk of severe bradycardia and heart block. 2, 3
Dofetilide: Absolute contraindication. 2

Use with Caution

Digoxin, amiodarone, ivabradine: Additive bradycardic effects. 2
CYP3A4 inhibitors (diltiazem, verapamil): Elevate propranolol concentrations. 2

Special Considerations

Insulin or oral hypoglycemics: Propranolol masks hypoglycemia symptoms; use with extreme caution in diabetics. 2, 3
Epinephrine-containing local anesthetics: Limit dosage; avoid gingival retraction cord with epinephrine; monitor BP 5 minutes post-administration. 6

Alternative Therapies

When Propranolol Is Contraindicated

Clinical Situation	Alternative Agent	Typical Adult Dose	Notes
Asthma/COPD	Metoprolol tartrate	25 mg BID; max 200 mg BID	β₁-selective; still carries bronchospasm risk [2]
Asthma/COPD	Metoprolol succinate (ER)	50 mg QD; max 400 mg QD	Once-daily β₁-selective [2]
Renal dysfunction	Metoprolol (no renal adjustment)	25–50 mg/day	No renal dose adjustment required [2]
Renal dysfunction	Atenolol	25–50 mg QD; max 100 mg QD	Requires renal dose adjustment [2]
Renal dysfunction	Nadolol	40 mg QD; max 320 mg QD	Requires renal dose adjustment [2]
Rate control (non-beta-blocker)	Diltiazem or verapamil	Varies	Not effective for tremor/anxiety [2]

Chronic Anxiety Disorders

SSRIs (escitalopram, sertraline) or SNRIs (venlafaxine) are first-line for chronic generalized anxiety; propranolol is not recommended. 2

Hypertension First-Line

ACE inhibitors, ARBs, calcium-channel blockers, thiazide diuretics are preferred over propranolol. 2

Common Pitfalls and Caveats

Dosing Errors

Do not use 1:1 mg conversion when switching from atenolol; atenolol 75 mg requires propranolol 120–160 mg/day for equivalent effect. 2
Immediate-release requires 2–4 times daily dosing (half-life 3–6 hours); extended-release allows once-daily dosing (half-life 8–20 hours). 2, 7

Patient Selection Mistakes

Propranolol is ineffective for chronic daily anxiety with predominantly psychological symptoms (worry, rumination); reserve for situational anxiety with somatic symptoms. 2
Do not prescribe for generalized social anxiety disorder; evidence is negative. 2

Safety Oversights

Failing to taper after chronic use precipitates rebound phenomena. 2, 3
Combining with diltiazem/verapamil without recognizing severe bradycardia risk. 2, 3
Prescribing to diabetics without counseling on hypoglycemia masking. 2, 3

Administration Errors (Pediatric)

Dosing during fasting states increases hypoglycemia risk; always give with or after feeding. 2
Exceeding 8-hour dosing intervals (6 hours in young infants) leads to subtherapeutic levels. 2

Monitoring Gaps

Routine vital signs are unnecessary in stable adults, but clinicians often over-monitor. 2
Failing to reassess HR/BP 1–2 hours after first dose in high-risk pediatric patients. 2

Special Populations

Diabetic Patients

Propranolol masks adrenergic hypoglycemia symptoms (tremor, tachycardia, sweating). 2, 3
Increase glucose monitoring frequency and rely on non-adrenergic cues (hunger, confusion). 2

Elderly Patients

Lower doses may be required due to altered pharmacokinetics. 2

Pregnant/Childbearing Women

Propranolol is not contraindicated in pregnancy (unlike ACE inhibitors/ARBs), but use only when benefit outweighs risk. 1

Athletes

May impair athletic performance through reduced exercise tolerance. 1

Pharmacokinetics

Immediate-release half-life: 3–6 hours (requires multiple daily doses). 2, 7
Extended-release half-life: 8–20 hours (allows once-daily dosing). 2, 7
IV half-life: 2.4 hours. 2
Bioavailability: Long-acting formulation is 30–50% less bioavailable than immediate-release due to increased first-pass metabolism. 7
Metabolism: CYP2D6, CYP1A2, CYP2C19. 2
CNS penetration: Readily crosses blood-brain barrier. 8, 9

What are the indications, adult and pediatric dosing regimens, contraindications, adverse effects, monitoring parameters, tapering recommendations, and alternative therapies for propranolol?

Help us tailor your experience